Physiomics PLC Notice of General Meeting (7193H)
August 22 2016 - 2:00AM
UK Regulatory
TIDMPYC
RNS Number : 7193H
Physiomics PLC
22 August 2016
22 August 2016
Physiomics plc
("Physiomics") or ("the Company")
Shareholder Circular and Notice of General Meeting
Physiomics plc (AIM: PYC), the Oxford, UK based systems biology
company, is pleased to announce that it has today published and
posted to shareholders a circular in relation to a forthcoming
General Meeting, due to be held at the Company's registered office,
The Magdalen Centre, Oxford Science Park, Robert Robinson Avenue,
Oxford, OX4 4GA at 10:00 a.m. on 7th September 2016.
The directors will propose at the General Meeting shareholder
resolutions seeking consent to allot shares and for the
dis-application of pre-emptive rights.
A copy of the Circular is available on the Company's website
(www.physiomics-plc.com/investors/reports-prospectus/).
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
WH Ireland Limited (nomad/joint broker)
Katy Mitchell
+44 (0) 161 832 2174
Hybridan LLP (joint broker)
Claire Louise Noyce
+44 (0) 203 764 2341
About Physiomics plc
Physiomics (AIM:PYC) is a computational systems biology services
company applying simulations of cell behaviour to drug development
to reduce the high attrition rates of clinical trials. 80-90 per
cent of all clinical drug candidates fail to reach the market and
estimates show that an overall ten per cent improvement in success
rates could reduce the cost of one drug's development by as much as
$242 million, from the current estimate of around $800 million(1)
.
Physiomics develops computational systems biology models to
predict and understand cancer drug efficacy from pre-clinical
research to clinical development. Physiomics has created detailed
mathematical models incorporating the most important molecular
events taking place during the human cell cycle and apoptosis
processes. The company's SystemCell(R) technology enables the
simulation of populations of "virtual cells". The company has also
developed a "Virtual Tumour" model to simulate the effect of
anti-cancer drugs on tumour growth. The models are used to optimise
compound design and to design drug schedules and combination
therapies.
Physiomics, based in Oxford, UK, was founded in 2001, and
floated on AIM in 2004. For further information, please visit
www.physiomics-plc.com
SystemCell(R) is a registered trademark of Physiomics plc
(1) Tufts Centre Impact Report 2002
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOAEASPNFDSKEFF
(END) Dow Jones Newswires
August 22, 2016 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
Historical Stock Chart
From Apr 2024 to May 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From May 2023 to May 2024